

## ADDYI<sup>®</sup> SUPPORT PROGRAM

### Dear Healthcare Professional:

Your patient has been prescribed **ADDYI<sup>®</sup>**, the first medication indicated for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in Canada. Download an **ADDYI<sup>®</sup> Support Program** card along with their prescription.

This multi-use benefit will cover up to 20% of the total prescription cost when used with a prescription.

For more information on the **ADDYI<sup>®</sup> Support Program**, please contact STI Customer Support at 1-877-790-1991.

**ADDYI<sup>®</sup>** is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire for a minimum of 6 months, which occurs 75-100% of the time, that causes marked distress or interpersonal difficulty and is NOT due to: a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.

**ADDYI<sup>®</sup>** is not indicated for the treatment of HSDD in menopausal or postmenopausal women or in men, and not indicated to enhance sexual performance.

**Clinical use:** Acquired” refers to HSDD in patients who previously had no problem with sexual desire. “Generalized” refers to HSDD that occurs regardless of the type of stimulation, situation or partner. There is no normative age-or gender-related data on frequency or degree of sexual desire. Therefore, the diagnosis must rely on clinical judgement based on the individual’s characteristics, interpersonal determinants, life context and cultural settings. The clinician may need to assess both partners when discrepancies in sexual desire prompt the call for professional attention. When making the diagnosis, it is recommended to use the **ADDYI<sup>®</sup>** Prescriber Checklist, available at [addyi.ca](http://addyi.ca).

Safety and efficacy of **ADDYI<sup>®</sup>** has not been established in patients >55 or <18 years of age. Please consult the Product Monograph at [https://pdf.hres.ca/dpd\\_pm/00053438.PDF](https://pdf.hres.ca/dpd_pm/00053438.PDF) for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, patient selection and dosing information. The Product Monograph is also available by calling our medical information department at: 1-833-881-5408.

Sincerely,

**Sprout Pharmaceuticals Canada, Ltd.**

